Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Dezember 2018 06:30 ET | Quelle: Veru Inc.

Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter

-- Advancing Multiple Drug Candidates, Two Drugs Currently in Clinical Trials, Company Transforming into Biopharmaceutical with Focus on Prostate Cancer, Successfully Completes Stock Offering, Awarded...
06. Dezember 2018 08:30 ET | Quelle: Veru Inc.

Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th

MIAMI, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that on Thursday, December 13, 2018, the company will report...
03. Dezember 2018 08:30 ET | Quelle: Veru Inc.

Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia

-- Combination Tablet Treats BPH Symptoms; Shrinks Prostate and Prevents BPH Progression -- -- NDA Submission Target Mid 2019 -- MIAMI, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU),...
13. November 2018 08:30 ET | Quelle: Veru Inc.

Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer

-- Submits Investigational New Drug Application to FDA -- -- Open Label Phase 1b/2 Clinical Trial Expected to Begin before end of 2018 -- MIAMI, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Veru Inc....
01. Oktober 2018 07:30 ET | Quelle: Veru Inc.

First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy

MIAMI, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced the enrollment of the first patient in its Phase 2 study of...
27. September 2018 17:00 ET | Quelle: Veru Inc.

Veru to Present at Upcoming Healthcare Investor Conferences in New York

MIAMI, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the company’s Chairman, President and Chief Executive...
27. September 2018 09:05 ET | Quelle: Veru Inc.

Veru Announces Pricing of Public Offering of Common Stock

MIAMI, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced the pricing of an underwritten public offering of 7,142,857 ...
26. September 2018 16:01 ET | Quelle: Veru Inc.

Veru Announces Proposed Public Offering of Common Stock

MIAMI, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it intends to offer and sell, subject to market...
12. September 2018 08:00 ET | Quelle: Veru Inc.

Veru has Successful Pre-IND Meeting with FDA for VERU-111 Next Generation Novel Oral Anti-Tubulin Therapy for Metastatic Prostate Cancer

MIAMI, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that it has completed a Pre-Investigational New Drug...
30. August 2018 08:00 ET | Quelle: Veru Inc.

Veru to Ring NASDAQ Closing Bell on August 31 to Kick Off National Prostate Cancer Awareness Month

MIAMI, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that that it has been invited by NASDAQ to ring the closing bell...

Vorherige Seite